Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
IncobotulinumtoxinA (Xeomin) is a botulinum toxin type A preparation free from complexing proteins, i.e. free from proteins other than the active toxin. Injected into the muscle, incobotulinumtoxinA (Xeomin) causes local weakening. Botulinum toxin type A is widely used for treatment of various neurological conditions. This study will investigate the efficacy and safety of incobotulinumtoxinA (Xeomin) in the treatment of post-stroke spasticity of the upper limb.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| IncobotulinumtoxinA (Xeomin) | Experimental | incobotulinumtoxinA (Xeomin, also known as "NT 201" or "Botulinum toxin type A (150 kiloDalton), free from complexing proteins") (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), up to five injections in the Open-Label Extension Period, up to 400 units at each injection visit; Mode of administration: intramuscular injection |
|
| Placebo | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| IncobotulinumtoxinA (Xeomin) | Drug | incobotulinumtoxinA (Xeomin, also known as "NT 201" or "Botulinum toxin type A (150 kiloDalton), free from complexing proteins") (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), up to five injections in the Open-Label Extension Period, up to 400 units at each injection visit; Mode of administration: intramuscular injection |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With Reduction of at Least 1 Point at Week 4 Compared to Baseline in Ashworth Score in Wrist Flexors | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Baseline, Week 4 |
| Measure | Description | Time Frame |
|---|---|---|
| Responders at Week 4 Based on a Responder Definition of at Least 2 Points Improvement From Baseline in the Ashworth Score for Wrist Flexors | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. |
| Measure | Description | Time Frame |
|---|---|---|
| Onset of Treatment Effect [Classified] | Starting with the visit 2 weeks after baseline injection the subject was asked if he/she experienced an treatment effect and if "yes": when. If the subject did not experience an treatment effect he/she was asked again at each of the following visits (at week 4, 8, and 12) of the Main Period until the answer was "yes" or until the final visit of the Main Period was performed. For subjects without any treatment effect the time to onset of effect was censored at the last visit of the Main Period. |
Main Inclusion Criteria:
Main Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Merz Pharmaceuticals | Merz Pharmaceuticals GmbH | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Czech Republic | Czechia | |||||
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | incobotulinumtoxinA (Xeomin) | incobotulinumtoxinA (Xeomin) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection |
| FG001 | Placebo | Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection Dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl; Mode of administration: intramuscular injection |
| Title | Milestones | Reasons Not Completed | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Main Period |
|
| |||||||||||||||||||||
| Open-Label Extension Period |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | incobotulinumtoxinA (Xeomin) | incobotulinumtoxinA (Xeomin) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection |
| BG001 | Placebo |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Participants With Reduction of at Least 1 Point at Week 4 Compared to Baseline in Ashworth Score in Wrist Flexors | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Intention to treat (ITT) as defined as all randomized subjects; missing values were not imputed | Posted | Number | Participants | Baseline, Week 4 |
|
All SAEs/AEs during Double-Blind Period After Injection.
The table of "Other Adverse Events" includes all AEs, both non serious and serious. Only results and AEs of the Double-Blind Period are given as the Open-Label Extension Period was a non-controlled study. The investigator asked the patient for AEs systematically at each visit.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | incobotulinumtoxinA (Xeomin) | incobotulinumtoxinA (Xeomin) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Bronchitis chronic | Respiratory, thoracic and mediastinal disorders | MedDRA (9.1) | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Contusion | Injury, poisoning and procedural complications | MedDRA (9.1) | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Angelika Hanschmann | Merz Pharmaceuticals GmbH | ++49-69-1503 | 538 | angelika.hanschmann@merz.de |
| ID | Term |
|---|---|
| C545476 | incobotulinumtoxinA |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Placebo | Drug | Placebo |
|
| Baseline, Week 4 |
| Responders Based on a Responder Definition of at Least 1 Point Improvement From Baseline in the Ashworth Score for Wrist Flexors at All Other Post Baseline Visits | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Baseline, Week 2, Week 8, Week 12, Final Visit of the Main Period (to be performed at week 12 after 1st injection at earliest, at week 20 at latest) |
| Responders Based on a Responder Definition of at Least 1 Point Improvement From Baseline in the Ashworth Score for Treated Elbow Flexors at All Post Baseline Visits | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Baseline, Week 2, Week 4, Week 8, Week 12, Final Visit of the Main Period (to be performed at week 12 after 1st injection at earliest, at week 20 at latest) |
| Responders Based on a Responder Definition of at Least 1 Point Improvement From Baseline in the Ashworth Score for Treated Forearm Pronators at All Post Baseline Visits | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Baseline, Week 2, Week 4, Week 8, Week 12, Final Visit of the Main Period (to be performed at week 12 after 1st injection at earliest, at week 20 at latest) |
| Responders Based on a Responder Definition of at Least 1 Point Improvement From Baseline in the Ashworth Score for Treated Finger Flexors at All Post Baseline Visits | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Baseline, Week 2, Week 4, Week 8, Week 12, Final Visit of the Main Period (to be performed at week 12 after 1st injection at earliest, at week 20 at latest) |
| Responders Based on a Responder Definition of at Least 1 Point Improvement From Baseline in the Ashworth Score for Treated Thumb Flexors at All Post Baseline Visits | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Baseline, Week 2, Week 4, Week 8, Week 12, Final Visit of the Main Period (to be performed at week 12 after 1st injection at earliest, at week 20 at latest) |
| Change From Baseline to Week 2 in Ashworth Scale Score for Treated Elbow Flexors | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Baseline, Week 2 |
| Change From Baseline to Week 4 in Ashworth Scale Score for Treated Elbow Flexors | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Baseline, Week 4 |
| Change From Baseline to Week 8 in Ashworth Scale Score for Treated Elbow Flexors | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Baseline, Week 8 |
| Change From Baseline to Week 12 in Ashworth Scale Score for Treated Elbow Flexors | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Baseline, Week 12 |
| Change From Baseline to Final Visit in Ashworth Scale Score for Treated Elbow Flexors | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Baseline, Final Visit of the Main Period (to be performed at week 12 after 1st injection at earliest, at week 20 at latest) |
| Change From Baseline to Week 2 in Ashworth Scale Score for Treated Forearm Pronators | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Baseline, Week 2 |
| Change From Baseline to Week 4 in Ashworth Scale Score for Treated Forearm Pronators | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Baseline, Week 4 |
| Change From Baseline to Week 8 in Ashworth Scale Score for Treated Forearm Pronators | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Baseline, Week 8 |
| Change From Baseline to Week 12 in Ashworth Scale Score for Treated Forearm Pronators | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Baseline, Week 12 |
| Change From Baseline to Final Visit in Ashworth Scale Score for Treated Forearm Pronators | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Baseline, Final Visit of the Main Period (to be performed at week 12 after 1st injection at earliest, at week 20 at latest) |
| Change From Baseline to Week 2 in Ashworth Scale Score for Wrist Flexors | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Baseline, Week 2 |
| Change From Baseline to Week 4 in Ashworth Scale Score for Wrist Flexors | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Baseline, Week 4 |
| Change From Baseline to Week 8 in Ashworth Scale Score for Wrist Flexors | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Baseline, Week 8 |
| Change From Baseline to Week 12 in Ashworth Scale Score for Wrist Flexors | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Baseline, Week 12 |
| Change From Baseline to Final Visit in Ashworth Scale Score for Wrist Flexors | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Baseline, Final Visit of the Main Period (to be performed at week 12 after 1st injection at earliest, at week 20 at latest) |
| Change From Baseline to Week 2 in Ashworth Scale Score for Finger Flexors | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Baseline, Week 2 |
| Change From Baseline to Week 4 in Ashworth Scale Score for Finger Flexors | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Baseline, Week 4 |
| Change From Baseline to Week 8 in Ashworth Scale Score for Finger Flexors | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Baseline, Week 8 |
| Change From Baseline to Week 12 in Ashworth Scale Score for Finger Flexors | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Baseline, Week 12 |
| Change From Baseline to Final Visit in Ashworth Scale Score for Finger Flexors | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Baseline, Final Visit of the Main Period (to be performed at week 12 after 1st injection at earliest, at week 20 at latest) |
| Change From Baseline to Week 2 in Ashworth Scale Score for Treated Thumb Flexors | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Baseline, Week 2 |
| Change From Baseline to Week 4 in Ashworth Scale Score for Treated Thumb Flexors | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Baseline, Week 4 |
| Change From Baseline to Week 8 in Ashworth Scale Score for Treated Thumb Flexors | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Baseline, Week 8 |
| Change From Baseline to Week 12 in Ashworth Scale Score for Treated Thumb Flexors | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Baseline, Week 12 |
| Change From Baseline to Final Visit in Ashworth Scale Score for Treated Thumb Flexors | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Baseline, Final Visit of the Main Period (to be performed at week 12 after 1st injection at earliest, at week 20 at latest) |
| Time to Onset of Treatment Effect | Starting with the visit 2 weeks after baseline injection the subject was asked if he/she experienced an treatment effect and if "yes": when. If the subject did not experience an treatment effect he/she was asked again at each of the following visits (at week 4, 8, and 12) of the Main Period until the answer was "yes" or until the final visit of the Main Period was performed. For subjects without any treatment effect the time to onset of effect was censored at the last visit of the Main Period. | Period starting at Visit 2 (baseline injection) of the Main Period up to onset of treatment effect |
| Time to Waning of Treatment Effect | Subject who reported an onset of treatment effect were asked at each visit/telephone contact starting at week 4 at earliest if he/she felt that there was a waning of the treatment effect. The same question was asked at each of the following telephone contacts and visits (up to the Final Visit of the Main Period) if the answer at the respective previous visit was "no". If the patient answered with "yes" he/she will be asked at which week after the injection (= the time span in weeks) the waning of effect occurred. For all subjects without an onset of treatment effect the waning was set to zero. | Defined as time (weeks) from Visit 2 (injection session at Baseline, Day 0) to the subjective estimation of the waning of the effect |
| Duration of Treatment Effect | The duration of treatment effect is defined as the time period from the day of injection until the time point of a need for a new injection agreed by the patient and the investigator. For subjects without any treatment effect the duration of effect was set to zero. | Period from the day of injection until the time point of a need for a new injection agreed by the patient and the investigator |
| Investigator's Global Assessment of Efficacy | The Investigator's Global Assessment of Efficacy is a subjective estimation assessed on a 4-point Likert scale with the items 1=very good, 2=good, 3=moderate, and 4=poor. | Final Visit of the Main Period (to be performed at week 12 after 1st injection at earliest, at week 20 at latest) |
| Patient's Global Assessment of Efficacy | The Patient's Global Assessment of Efficacy is a subjective estimation assessed on a 4-point Likert scale with the items 1=very good, 2=good, 3=moderate, and 4=poor. | Final Visit of the Main Period (to be performed at week 12 after 1st injection at earliest, at week 20 at latest) |
| Carer's Global Assessment of Efficacy | The Carer's Global Assessment of Efficacy is a subjective estimation assessed on a 4-point Likert scale with the items 1=very good, 2=good, 3=moderate, and 4=poor. | Final Visit of the Main Period (to be performed at week 12 after 1st injection at earliest, at week 20 at latest) |
| Change From Baseline to Week 2 in the Disability Assessment Scale for the Principal Therapeutic Target | The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability). | Baseline, Week 2 |
| Change From Baseline to Week 4 in the Disability Assessment Scale for the Principal Therapeutic Target | The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability). | Baseline, Week 4 |
| Change From Baseline to Week 8 in the Disability Assessment Scale for the Principal Therapeutic Target | The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability). | Baseline, Week 8 |
| Change From Baseline to Week 12 in the Disability Assessment Scale for the Principal Therapeutic Target | The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability). | Baseline, Week 12 |
| Change From Baseline to Final Visit in the Disability Assessment Scale for the Principal Therapeutic Target | The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability). | Baseline, Final Visit of the Main Period (to be performed at week 12 after 1st injection at earliest, at week 20 at latest) |
| Change From Baseline to Week 2 in the Disability Assessment Scale for Domain "Hygiene" | The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability). | Baseline, Week 2 |
| Change From Baseline to Week 4 in the Disability Assessment Scale for Domain "Hygiene" | The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability). | Baseline, Week 4 |
| Change From Baseline to Week 8 in the Disability Assessment Scale for Domain "Hygiene" | The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability). | Baseline, Week 8 |
| Change From Baseline to Week 12 in the Disability Assessment Scale for Domain "Hygiene" | The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability). | Baseline, Week 12 |
| Change From Baseline to Final Visit in the Disability Assessment Scale for Domain "Hygiene" | The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability). | Baseline, Final Visit of the Main Period (to be performed at week 12 after 1st injection at earliest, at week 20 at latest) |
| Change From Baseline to Week 2 in the Disability Assessment Scale for Domain "Dressing" | The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability). | Baseline, Week 2 |
| Change From Baseline to Week 4 in the Disability Assessment Scale for Domain "Dressing" | The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability). | Baseline, Week 4 |
| Change From Baseline to Week 8 in the Disability Assessment Scale for Domain "Dressing" | The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability). | Baseline, Week 8 |
| Change From Baseline to Week 12 in the Disability Assessment Scale for Domain "Dressing" | The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability). | Baseline, Week 12 |
| Change From Baseline to Final Visit in the Disability Assessment Scale for Domain "Dressing" | The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability). | Baseline, Final Visit of the Main Period (to be performed at week 12 after 1st injection at earliest, at week 20 at latest) |
| Change From Baseline to Week 2 in the Disability Assessment Scale for Domain "Limb Position" | The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability). | Baseline, Week 2 |
| Change From Baseline to Week 4 in the Disability Assessment Scale for Domain "Limb Position" | The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability). | Baseline, Week 4 |
| Change From Baseline to Week 8 in the Disability Assessment Scale for Domain "Limb Position" | The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability). | Baseline, Week 8 |
| Change From Baseline to Week 12 in the Disability Assessment Scale for Domain "Limb Position" | The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability). | Baseline, Week 12 |
| Change From Baseline to Final Visit in the Disability Assessment Scale for Domain "Limb Position" | The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability). | Baseline, Final Visit of the Main Period (to be performed at week 12 after 1st injection at earliest, at week 20 at latest) |
| Change From Baseline to Week 2 in the Disability Assessment Scale for Domain "Pain" | The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability). | Baseline, Week 2 |
| Change From Baseline to Week 4 in the Disability Assessment Scale for Domain "Pain" | The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability). | Baseline, Week 4 |
| Change From Baseline to Week 8 in the Disability Assessment Scale for Domain "Pain" | The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability). | Baseline, Week 8 |
| Change From Baseline to Week 12 in the Disability Assessment Scale for Domain "Pain" | The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability). | Baseline, Week 12 |
| Change From Baseline to Final Visit in the Disability Assessment Scale for Domain "Pain" | The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability). | Baseline, Final Visit of the Main Period (to be performed at week 12 after 1st injection at earliest, at week 20 at latest) |
| Change From Baseline to Week 4 in the Carer Burden Scale for Domain "Cleaning the Palm of the Affected Hand" | The Carer Burden Scale evaluates the impact of antispastic medication on the physical burden of the carer. It consists of the following items: A=cleaning the palm of the affected hand; B=cutting the fingernails of the affected hand; C=Cleaning the armpit of the affected arm; D=putting the affected arm through the sleeve; E=applying a splint on the affected arm. Each item was assessed on a 5-point Likert scale which values ranges from 0 (=no difficulty) to 4 (=cannot do the task). | Baseline, Week 4 |
| Change From Baseline to Week 12 in the Carer Burden Scale for Domain "Cleaning the Palm of the Affected Hand" | The Carer Burden Scale evaluates the impact of antispastic medication on the physical burden of the carer. It consists of the following items: A=cleaning the palm of the affected hand; B=cutting the fingernails of the affected hand; C=Cleaning the armpit of the affected arm; D=putting the affected arm through the sleeve; E=applying a splint on the affected arm. Each item was assessed on a 5-point Likert scale which values ranges from 0 (=no difficulty) to 4 (=cannot do the task). | Baseline, Week 12 |
| Change From Baseline to Final Visit in the Carer Burden Scale for Domain "Cleaning the Palm of the Affected Hand" | The Carer Burden Scale evaluates the impact of antispastic medication on the physical burden of the carer. It consists of the following items: A=cleaning the palm of the affected hand; B=cutting the fingernails of the affected hand; C=Cleaning the armpit of the affected arm; D=putting the affected arm through the sleeve; E=applying a splint on the affected arm. Each item was assessed on a 5-point Likert scale which values ranges from 0 (=no difficulty) to 4 (=cannot do the task). | Baseline, Final Visit of the Main Period (to be performed at week 12 after 1st injection at earliest, at week 20 at latest) |
| Change From Baseline to Week 4 in the Carer Burden Scale for Domain "Cutting the Fingernails of the Affected Hand" | The Carer Burden Scale evaluates the impact of antispastic medication on the physical burden of the carer. It consists of the following items: A=cleaning the palm of the affected hand; B=cutting the fingernails of the affected hand; C=Cleaning the armpit of the affected arm; D=putting the affected arm through the sleeve; E=applying a splint on the affected arm. Each item was assessed on a 5-point Likert scale which values ranges from 0 (=no difficulty) to 4 (=cannot do the task). | Baseline, Week 4 |
| Change From Baseline to Week 12 in the Carer Burden Scale for Domain "Cutting the Fingernails of the Affected Hand" | The Carer Burden Scale evaluates the impact of antispastic medication on the physical burden of the carer. It consists of the following items: A=cleaning the palm of the affected hand; B=cutting the fingernails of the affected hand; C=Cleaning the armpit of the affected arm; D=putting the affected arm through the sleeve; E=applying a splint on the affected arm. Each item was assessed on a 5-point Likert scale which values ranges from 0 (=no difficulty) to 4 (=cannot do the task). | Baseline, Week 12 |
| Change From Baseline to Final Visit in the Carer Burden Scale for Domain "Cutting the Fingernails of the Affected Hand" | The Carer Burden Scale evaluates the impact of antispastic medication on the physical burden of the carer. It consists of the following items: A=cleaning the palm of the affected hand; B=cutting the fingernails of the affected hand; C=Cleaning the armpit of the affected arm; D=putting the affected arm through the sleeve; E=applying a splint on the affected arm. Each item was assessed on a 5-point Likert scale which values ranges from 0 (=no difficulty) to 4 (=cannot do the task). | Baseline, Final Visit of the Main Period (to be performed at week 12 after 1st injection at earliest, at week 20 at latest) |
| Change From Baseline to Week 4 in the Carer Burden Scale for Domain "Cleaning the Armpit of the Affected Arm" | The Carer Burden Scale evaluates the impact of antispastic medication on the physical burden of the carer. It consists of the following items: A=cleaning the palm of the affected hand; B=cutting the fingernails of the affected hand; C=Cleaning the armpit of the affected arm; D=putting the affected arm through the sleeve; E=applying a splint on the affected arm. Each item was assessed on a 5-point Likert scale which values ranges from 0 (=no difficulty) to 4 (=cannot do the task). | Baseline, Week 4 |
| Change From Baseline to Week 12 in the Carer Burden Scale for Domain "Cleaning the Armpit of the Affected Arm" | The Carer Burden Scale evaluates the impact of antispastic medication on the physical burden of the carer. It consists of the following items: A=cleaning the palm of the affected hand; B=cutting the fingernails of the affected hand; C=Cleaning the armpit of the affected arm; D=putting the affected arm through the sleeve; E=applying a splint on the affected arm. Each item was assessed on a 5-point Likert scale which values ranges from 0 (=no difficulty) to 4 (=cannot do the task). | Baseline, Week 12 |
| Change From Baseline to Final Visit in the Carer Burden Scale for Domain "Cleaning the Armpit of the Affected Arm" | The Carer Burden Scale evaluates the impact of antispastic medication on the physical burden of the carer. It consists of the following items: A=cleaning the palm of the affected hand; B=cutting the fingernails of the affected hand; C=Cleaning the armpit of the affected arm; D=putting the affected arm through the sleeve; E=applying a splint on the affected arm. Each item was assessed on a 5-point Likert scale which values ranges from 0 (=no difficulty) to 4 (=cannot do the task). | Baseline, Final Visit of the Main Period (to be performed at week 12 after 1st injection at earliest, at week 20 at latest) |
| Change From Baseline to Week 4 in the Carer Burden Scale for Domain "Putting the Affected Arm Through the Sleeve (e.g., Coat, Shirt, Jacket)" | The Carer Burden Scale evaluates the impact of antispastic medication on the physical burden of the carer. It consists of the following items: A=cleaning the palm of the affected hand; B=cutting the fingernails of the affected hand; C=Cleaning the armpit of the affected arm; D=putting the affected arm through the sleeve; E=applying a splint on the affected arm. Each item was assessed on a 5-point Likert scale which values ranges from 0 (=no difficulty) to 4 (=cannot do the task). | Baseline, Week 4 |
| Change From Baseline to Week 12 in the Carer Burden Scale for Domain "Putting the Affected Arm Through the Sleeve (e.g., Coat, Shirt, Jacket)" | The Carer Burden Scale evaluates the impact of antispastic medication on the physical burden of the carer. It consists of the following items: A=cleaning the palm of the affected hand; B=cutting the fingernails of the affected hand; C=Cleaning the armpit of the affected arm; D=putting the affected arm through the sleeve; E=applying a splint on the affected arm. Each item was assessed on a 5-point Likert scale which values ranges from 0 (=no difficulty) to 4 (=cannot do the task). | Baseline, Week 12 |
| Change From Baseline to Final Visit in the Carer Burden Scale for Domain "Putting the Affected Arm Through the Sleeve (e.g., Coat, Shirt, Jacket)" | The Carer Burden Scale evaluates the impact of antispastic medication on the physical burden of the carer. It consists of the following items: A=cleaning the palm of the affected hand; B=cutting the fingernails of the affected hand; C=Cleaning the armpit of the affected arm; D=putting the affected arm through the sleeve; E=applying a splint on the affected arm. Each item was assessed on a 5-point Likert scale which values ranges from 0 (=no difficulty) to 4 (=cannot do the task). | Baseline, Final Visit of the Main Period (to be performed at week 12 after 1st injection at earliest, at week 20 at latest) |
| Change From Baseline to Week 4 in the Carer Burden Scale for Domain "Applying a Splint on the Affected Arm" | The Carer Burden Scale evaluates the impact of antispastic medication on the physical burden of the carer. It consists of the following items: A=cleaning the palm of the affected hand; B=cutting the fingernails of the affected hand; C=Cleaning the armpit of the affected arm; D=putting the affected arm through the sleeve; E=applying a splint on the affected arm. Each item was assessed on a 5-point Likert scale which values ranges from 0 (=no difficulty) to 4 (=cannot do the task). | Baseline, Week 4 |
| Change From Baseline to Week 12 in the Carer Burden Scale for Domain "Applying a Splint on the Affected Arm" | The Carer Burden Scale evaluates the impact of antispastic medication on the physical burden of the carer. It consists of the following items: A=cleaning the palm of the affected hand; B=cutting the fingernails of the affected hand; C=Cleaning the armpit of the affected arm; D=putting the affected arm through the sleeve; E=applying a splint on the affected arm. Each item was assessed on a 5-point Likert scale which values ranges from 0 (=no difficulty) to 4 (=cannot do the task). | Baseline, Week 12 |
| Change From Baseline to Final Visit in the Carer Burden Scale for Domain "Applying a Splint on the Affected Arm" | The Carer Burden Scale evaluates the impact of antispastic medication on the physical burden of the carer. It consists of the following items: A=cleaning the palm of the affected hand; B=cutting the fingernails of the affected hand; C=Cleaning the armpit of the affected arm; D=putting the affected arm through the sleeve; E=applying a splint on the affected arm. Each item was assessed on a 5-point Likert scale which values ranges from 0 (=no difficulty) to 4 (=cannot do the task). | Baseline, Final Visit of the Main Period (to be performed at week 12 after 1st injection at earliest, at week 20 at latest) |
| Period starting at baseline injection of the Main Period up to onset of treatment effect |
| Hungary |
| Hungary |
| Poland | Poland |
| NOT COMPLETED |
|
|
Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection Dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl; Mode of administration: intramuscular injection
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| OG001 | Placebo | Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection Dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl; Mode of administration: intramuscular injection |
|
|
|
| Secondary | Responders at Week 4 Based on a Responder Definition of at Least 2 Points Improvement From Baseline in the Ashworth Score for Wrist Flexors | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Intention to treat (ITT) as defined as all randomized subjects; missing values were imputed by worst case, i.e. zero change | Posted | Number | Participants | Baseline, Week 4 |
|
|
|
| Secondary | Responders Based on a Responder Definition of at Least 1 Point Improvement From Baseline in the Ashworth Score for Wrist Flexors at All Other Post Baseline Visits | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Intention to treat (ITT) as defined as all randomized subjects; missing values were imputed by worst case, i.e. zero change | Posted | Number | Participants | Baseline, Week 2, Week 8, Week 12, Final Visit of the Main Period (to be performed at week 12 after 1st injection at earliest, at week 20 at latest) |
|
|
|
| Secondary | Responders Based on a Responder Definition of at Least 1 Point Improvement From Baseline in the Ashworth Score for Treated Elbow Flexors at All Post Baseline Visits | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Intention to treat (ITT) as defined as all randomized subjects; missing values were imputed by worst case, i.e. zero change | Posted | Number | Participants | Baseline, Week 2, Week 4, Week 8, Week 12, Final Visit of the Main Period (to be performed at week 12 after 1st injection at earliest, at week 20 at latest) |
|
|
|
| Secondary | Responders Based on a Responder Definition of at Least 1 Point Improvement From Baseline in the Ashworth Score for Treated Forearm Pronators at All Post Baseline Visits | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Intention to treat (ITT) as defined as all randomized subjects; missing values were imputed by worst case, i.e. zero change | Posted | Number | Participants | Baseline, Week 2, Week 4, Week 8, Week 12, Final Visit of the Main Period (to be performed at week 12 after 1st injection at earliest, at week 20 at latest) |
|
|
|
| Secondary | Responders Based on a Responder Definition of at Least 1 Point Improvement From Baseline in the Ashworth Score for Treated Finger Flexors at All Post Baseline Visits | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Intention to treat (ITT) as defined as all randomized subjects; missing values were imputed by worst case, i.e. zero change | Posted | Number | Participants | Baseline, Week 2, Week 4, Week 8, Week 12, Final Visit of the Main Period (to be performed at week 12 after 1st injection at earliest, at week 20 at latest) |
|
|
|
| Secondary | Responders Based on a Responder Definition of at Least 1 Point Improvement From Baseline in the Ashworth Score for Treated Thumb Flexors at All Post Baseline Visits | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Intention to treat (ITT) as defined as all randomized subjects; missing values were imputed by worst case, i.e. zero change | Posted | Number | Participants | Baseline, Week 2, Week 4, Week 8, Week 12, Final Visit of the Main Period (to be performed at week 12 after 1st injection at earliest, at week 20 at latest) |
|
|
|
| Secondary | Change From Baseline to Week 2 in Ashworth Scale Score for Treated Elbow Flexors | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Baseline, Week 2 |
|
|
|
| Secondary | Change From Baseline to Week 4 in Ashworth Scale Score for Treated Elbow Flexors | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Baseline, Week 4 |
|
|
|
| Secondary | Change From Baseline to Week 8 in Ashworth Scale Score for Treated Elbow Flexors | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Baseline, Week 8 |
|
|
|
| Secondary | Change From Baseline to Week 12 in Ashworth Scale Score for Treated Elbow Flexors | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Baseline, Week 12 |
|
|
|
| Secondary | Change From Baseline to Final Visit in Ashworth Scale Score for Treated Elbow Flexors | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Baseline, Final Visit of the Main Period (to be performed at week 12 after 1st injection at earliest, at week 20 at latest) |
|
|
|
| Secondary | Change From Baseline to Week 2 in Ashworth Scale Score for Treated Forearm Pronators | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Baseline, Week 2 |
|
|
|
| Secondary | Change From Baseline to Week 4 in Ashworth Scale Score for Treated Forearm Pronators | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Baseline, Week 4 |
|
|
|
| Secondary | Change From Baseline to Week 8 in Ashworth Scale Score for Treated Forearm Pronators | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Baseline, Week 8 |
|
|
|
| Secondary | Change From Baseline to Week 12 in Ashworth Scale Score for Treated Forearm Pronators | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Baseline, Week 12 |
|
|
|
| Secondary | Change From Baseline to Final Visit in Ashworth Scale Score for Treated Forearm Pronators | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Baseline, Final Visit of the Main Period (to be performed at week 12 after 1st injection at earliest, at week 20 at latest) |
|
|
|
| Secondary | Change From Baseline to Week 2 in Ashworth Scale Score for Wrist Flexors | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Baseline, Week 2 |
|
|
|
| Secondary | Change From Baseline to Week 4 in Ashworth Scale Score for Wrist Flexors | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Baseline, Week 4 |
|
|
|
| Secondary | Change From Baseline to Week 8 in Ashworth Scale Score for Wrist Flexors | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Baseline, Week 8 |
|
|
|
| Secondary | Change From Baseline to Week 12 in Ashworth Scale Score for Wrist Flexors | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Baseline, Week 12 |
|
|
|
| Secondary | Change From Baseline to Final Visit in Ashworth Scale Score for Wrist Flexors | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Baseline, Final Visit of the Main Period (to be performed at week 12 after 1st injection at earliest, at week 20 at latest) |
|
|
|
| Secondary | Change From Baseline to Week 2 in Ashworth Scale Score for Finger Flexors | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Baseline, Week 2 |
|
|
|
| Secondary | Change From Baseline to Week 4 in Ashworth Scale Score for Finger Flexors | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Baseline, Week 4 |
|
|
|
| Secondary | Change From Baseline to Week 8 in Ashworth Scale Score for Finger Flexors | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Baseline, Week 8 |
|
|
|
| Secondary | Change From Baseline to Week 12 in Ashworth Scale Score for Finger Flexors | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Baseline, Week 12 |
|
|
|
| Secondary | Change From Baseline to Final Visit in Ashworth Scale Score for Finger Flexors | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Baseline, Final Visit of the Main Period (to be performed at week 12 after 1st injection at earliest, at week 20 at latest) |
|
|
|
| Secondary | Change From Baseline to Week 2 in Ashworth Scale Score for Treated Thumb Flexors | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Baseline, Week 2 |
|
|
|
| Secondary | Change From Baseline to Week 4 in Ashworth Scale Score for Treated Thumb Flexors | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Baseline, Week 4 |
|
|
|
| Secondary | Change From Baseline to Week 8 in Ashworth Scale Score for Treated Thumb Flexors | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Baseline, Week 8 |
|
|
|
| Secondary | Change From Baseline to Week 12 in Ashworth Scale Score for Treated Thumb Flexors | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Baseline, Week 12 |
|
|
|
| Secondary | Change From Baseline to Final Visit in Ashworth Scale Score for Treated Thumb Flexors | The Ashworth Scale is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the primary efficacy analysis. | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Baseline, Final Visit of the Main Period (to be performed at week 12 after 1st injection at earliest, at week 20 at latest) |
|
|
|
| Secondary | Time to Onset of Treatment Effect | Starting with the visit 2 weeks after baseline injection the subject was asked if he/she experienced an treatment effect and if "yes": when. If the subject did not experience an treatment effect he/she was asked again at each of the following visits (at week 4, 8, and 12) of the Main Period until the answer was "yes" or until the final visit of the Main Period was performed. For subjects without any treatment effect the time to onset of effect was censored at the last visit of the Main Period. | Results for placebo patients were not displayed because the upper limit of the confidence interval was not estimable (this can not be entered because a numeric entry is expected). The results of this analysis are therefore given as "Onset of Treatment Effect [classified]" under "Other Pre-specified Outcome". | Posted | Median | 95% Confidence Interval | Days | Period starting at Visit 2 (baseline injection) of the Main Period up to onset of treatment effect |
|
|
|
| Secondary | Time to Waning of Treatment Effect | Subject who reported an onset of treatment effect were asked at each visit/telephone contact starting at week 4 at earliest if he/she felt that there was a waning of the treatment effect. The same question was asked at each of the following telephone contacts and visits (up to the Final Visit of the Main Period) if the answer at the respective previous visit was "no". If the patient answered with "yes" he/she will be asked at which week after the injection (= the time span in weeks) the waning of effect occurred. For all subjects without an onset of treatment effect the waning was set to zero. | Posted | Median | 95% Confidence Interval | Weeks | Defined as time (weeks) from Visit 2 (injection session at Baseline, Day 0) to the subjective estimation of the waning of the effect |
|
|
|
| Secondary | Duration of Treatment Effect | The duration of treatment effect is defined as the time period from the day of injection until the time point of a need for a new injection agreed by the patient and the investigator. For subjects without any treatment effect the duration of effect was set to zero. | Posted | Median | 95% Confidence Interval | Days | Period from the day of injection until the time point of a need for a new injection agreed by the patient and the investigator |
|
|
|
| Other Pre-specified | Onset of Treatment Effect [Classified] | Starting with the visit 2 weeks after baseline injection the subject was asked if he/she experienced an treatment effect and if "yes": when. If the subject did not experience an treatment effect he/she was asked again at each of the following visits (at week 4, 8, and 12) of the Main Period until the answer was "yes" or until the final visit of the Main Period was performed. For subjects without any treatment effect the time to onset of effect was censored at the last visit of the Main Period. | These results are a different presentation of the results of the secondary outcome measure "Time to Onset of Treatment Effect". For subjects without any treatment effect the time to onset of effect was censored at the last visit. | Posted | Number | Participants | Period starting at baseline injection of the Main Period up to onset of treatment effect |
|
|
|
| Secondary | Investigator's Global Assessment of Efficacy | The Investigator's Global Assessment of Efficacy is a subjective estimation assessed on a 4-point Likert scale with the items 1=very good, 2=good, 3=moderate, and 4=poor. | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Final Visit of the Main Period (to be performed at week 12 after 1st injection at earliest, at week 20 at latest) |
|
|
|
| Secondary | Patient's Global Assessment of Efficacy | The Patient's Global Assessment of Efficacy is a subjective estimation assessed on a 4-point Likert scale with the items 1=very good, 2=good, 3=moderate, and 4=poor. | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Final Visit of the Main Period (to be performed at week 12 after 1st injection at earliest, at week 20 at latest) |
|
|
|
| Secondary | Carer's Global Assessment of Efficacy | The Carer's Global Assessment of Efficacy is a subjective estimation assessed on a 4-point Likert scale with the items 1=very good, 2=good, 3=moderate, and 4=poor. | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Final Visit of the Main Period (to be performed at week 12 after 1st injection at earliest, at week 20 at latest) |
|
|
|
| Secondary | Change From Baseline to Week 2 in the Disability Assessment Scale for the Principal Therapeutic Target | The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability). | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Baseline, Week 2 |
|
|
|
| Secondary | Change From Baseline to Week 4 in the Disability Assessment Scale for the Principal Therapeutic Target | The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability). | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Baseline, Week 4 |
|
|
|
| Secondary | Change From Baseline to Week 8 in the Disability Assessment Scale for the Principal Therapeutic Target | The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability). | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Baseline, Week 8 |
|
|
|
| Secondary | Change From Baseline to Week 12 in the Disability Assessment Scale for the Principal Therapeutic Target | The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability). | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Baseline, Week 12 |
|
|
|
| Secondary | Change From Baseline to Final Visit in the Disability Assessment Scale for the Principal Therapeutic Target | The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability). | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Baseline, Final Visit of the Main Period (to be performed at week 12 after 1st injection at earliest, at week 20 at latest) |
|
|
|
| Secondary | Change From Baseline to Week 2 in the Disability Assessment Scale for Domain "Hygiene" | The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability). | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Baseline, Week 2 |
|
|
|
| Secondary | Change From Baseline to Week 4 in the Disability Assessment Scale for Domain "Hygiene" | The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability). | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Baseline, Week 4 |
|
|
|
| Secondary | Change From Baseline to Week 8 in the Disability Assessment Scale for Domain "Hygiene" | The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability). | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Baseline, Week 8 |
|
|
|
| Secondary | Change From Baseline to Week 12 in the Disability Assessment Scale for Domain "Hygiene" | The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability). | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Baseline, Week 12 |
|
|
|
| Secondary | Change From Baseline to Final Visit in the Disability Assessment Scale for Domain "Hygiene" | The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability). | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Baseline, Final Visit of the Main Period (to be performed at week 12 after 1st injection at earliest, at week 20 at latest) |
|
|
|
| Secondary | Change From Baseline to Week 2 in the Disability Assessment Scale for Domain "Dressing" | The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability). | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Baseline, Week 2 |
|
|
|
| Secondary | Change From Baseline to Week 4 in the Disability Assessment Scale for Domain "Dressing" | The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability). | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Baseline, Week 4 |
|
|
|
| Secondary | Change From Baseline to Week 8 in the Disability Assessment Scale for Domain "Dressing" | The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability). | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Baseline, Week 8 |
|
|
|
| Secondary | Change From Baseline to Week 12 in the Disability Assessment Scale for Domain "Dressing" | The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability). | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Baseline, Week 12 |
|
|
|
| Secondary | Change From Baseline to Final Visit in the Disability Assessment Scale for Domain "Dressing" | The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability). | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Baseline, Final Visit of the Main Period (to be performed at week 12 after 1st injection at earliest, at week 20 at latest) |
|
|
|
| Secondary | Change From Baseline to Week 2 in the Disability Assessment Scale for Domain "Limb Position" | The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability). | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Baseline, Week 2 |
|
|
|
| Secondary | Change From Baseline to Week 4 in the Disability Assessment Scale for Domain "Limb Position" | The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability). | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Baseline, Week 4 |
|
|
|
| Secondary | Change From Baseline to Week 8 in the Disability Assessment Scale for Domain "Limb Position" | The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability). | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Baseline, Week 8 |
|
|
|
| Secondary | Change From Baseline to Week 12 in the Disability Assessment Scale for Domain "Limb Position" | The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability). | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Baseline, Week 12 |
|
|
|
| Secondary | Change From Baseline to Final Visit in the Disability Assessment Scale for Domain "Limb Position" | The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability). | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Baseline, Final Visit of the Main Period (to be performed at week 12 after 1st injection at earliest, at week 20 at latest) |
|
|
|
| Secondary | Change From Baseline to Week 2 in the Disability Assessment Scale for Domain "Pain" | The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability). | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Baseline, Week 2 |
|
|
|
| Secondary | Change From Baseline to Week 4 in the Disability Assessment Scale for Domain "Pain" | The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability). | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Baseline, Week 4 |
|
|
|
| Secondary | Change From Baseline to Week 8 in the Disability Assessment Scale for Domain "Pain" | The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability). | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Baseline, Week 8 |
|
|
|
| Secondary | Change From Baseline to Week 12 in the Disability Assessment Scale for Domain "Pain" | The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability). | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Baseline, Week 12 |
|
|
|
| Secondary | Change From Baseline to Final Visit in the Disability Assessment Scale for Domain "Pain" | The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability). | Intention to treat (ITT) as defined as all randomized subjects | Posted | Number | Participants | Baseline, Final Visit of the Main Period (to be performed at week 12 after 1st injection at earliest, at week 20 at latest) |
|
|
|
| Secondary | Change From Baseline to Week 4 in the Carer Burden Scale for Domain "Cleaning the Palm of the Affected Hand" | The Carer Burden Scale evaluates the impact of antispastic medication on the physical burden of the carer. It consists of the following items: A=cleaning the palm of the affected hand; B=cutting the fingernails of the affected hand; C=Cleaning the armpit of the affected arm; D=putting the affected arm through the sleeve; E=applying a splint on the affected arm. Each item was assessed on a 5-point Likert scale which values ranges from 0 (=no difficulty) to 4 (=cannot do the task). | Intention to treat (ITT) as defined as all randomized subjects; missing values were imputed by baseline value, i.e. zero change | Posted | Number | Participants | Baseline, Week 4 |
|
|
|
| Secondary | Change From Baseline to Week 12 in the Carer Burden Scale for Domain "Cleaning the Palm of the Affected Hand" | The Carer Burden Scale evaluates the impact of antispastic medication on the physical burden of the carer. It consists of the following items: A=cleaning the palm of the affected hand; B=cutting the fingernails of the affected hand; C=Cleaning the armpit of the affected arm; D=putting the affected arm through the sleeve; E=applying a splint on the affected arm. Each item was assessed on a 5-point Likert scale which values ranges from 0 (=no difficulty) to 4 (=cannot do the task). | Intention to treat (ITT) as defined as all randomized subjects; missing values were imputed by baseline value, i.e. zero change | Posted | Number | Participants | Baseline, Week 12 |
|
|
|
| Secondary | Change From Baseline to Final Visit in the Carer Burden Scale for Domain "Cleaning the Palm of the Affected Hand" | The Carer Burden Scale evaluates the impact of antispastic medication on the physical burden of the carer. It consists of the following items: A=cleaning the palm of the affected hand; B=cutting the fingernails of the affected hand; C=Cleaning the armpit of the affected arm; D=putting the affected arm through the sleeve; E=applying a splint on the affected arm. Each item was assessed on a 5-point Likert scale which values ranges from 0 (=no difficulty) to 4 (=cannot do the task). | Intention to treat (ITT) as defined as all randomized subjects; missing values were imputed by baseline value, i.e. zero change | Posted | Number | Participants | Baseline, Final Visit of the Main Period (to be performed at week 12 after 1st injection at earliest, at week 20 at latest) |
|
|
|
| Secondary | Change From Baseline to Week 4 in the Carer Burden Scale for Domain "Cutting the Fingernails of the Affected Hand" | The Carer Burden Scale evaluates the impact of antispastic medication on the physical burden of the carer. It consists of the following items: A=cleaning the palm of the affected hand; B=cutting the fingernails of the affected hand; C=Cleaning the armpit of the affected arm; D=putting the affected arm through the sleeve; E=applying a splint on the affected arm. Each item was assessed on a 5-point Likert scale which values ranges from 0 (=no difficulty) to 4 (=cannot do the task). | Intention to treat (ITT) as defined as all randomized subjects; missing values were imputed by baseline value, i.e. zero change | Posted | Number | Participants | Baseline, Week 4 |
|
|
|
| Secondary | Change From Baseline to Week 12 in the Carer Burden Scale for Domain "Cutting the Fingernails of the Affected Hand" | The Carer Burden Scale evaluates the impact of antispastic medication on the physical burden of the carer. It consists of the following items: A=cleaning the palm of the affected hand; B=cutting the fingernails of the affected hand; C=Cleaning the armpit of the affected arm; D=putting the affected arm through the sleeve; E=applying a splint on the affected arm. Each item was assessed on a 5-point Likert scale which values ranges from 0 (=no difficulty) to 4 (=cannot do the task). | Intention to treat (ITT) as defined as all randomized subjects; missing values were imputed by baseline value, i.e. zero change | Posted | Number | Participants | Baseline, Week 12 |
|
|
|
| Secondary | Change From Baseline to Final Visit in the Carer Burden Scale for Domain "Cutting the Fingernails of the Affected Hand" | The Carer Burden Scale evaluates the impact of antispastic medication on the physical burden of the carer. It consists of the following items: A=cleaning the palm of the affected hand; B=cutting the fingernails of the affected hand; C=Cleaning the armpit of the affected arm; D=putting the affected arm through the sleeve; E=applying a splint on the affected arm. Each item was assessed on a 5-point Likert scale which values ranges from 0 (=no difficulty) to 4 (=cannot do the task). | Intention to treat (ITT) as defined as all randomized subjects; missing values were imputed by baseline value, i.e. zero change | Posted | Number | Participants | Baseline, Final Visit of the Main Period (to be performed at week 12 after 1st injection at earliest, at week 20 at latest) |
|
|
|
| Secondary | Change From Baseline to Week 4 in the Carer Burden Scale for Domain "Cleaning the Armpit of the Affected Arm" | The Carer Burden Scale evaluates the impact of antispastic medication on the physical burden of the carer. It consists of the following items: A=cleaning the palm of the affected hand; B=cutting the fingernails of the affected hand; C=Cleaning the armpit of the affected arm; D=putting the affected arm through the sleeve; E=applying a splint on the affected arm. Each item was assessed on a 5-point Likert scale which values ranges from 0 (=no difficulty) to 4 (=cannot do the task). | Intention to treat (ITT) as defined as all randomized subjects; missing values were imputed by baseline value, i.e. zero change | Posted | Number | Participants | Baseline, Week 4 |
|
|
|
| Secondary | Change From Baseline to Week 12 in the Carer Burden Scale for Domain "Cleaning the Armpit of the Affected Arm" | The Carer Burden Scale evaluates the impact of antispastic medication on the physical burden of the carer. It consists of the following items: A=cleaning the palm of the affected hand; B=cutting the fingernails of the affected hand; C=Cleaning the armpit of the affected arm; D=putting the affected arm through the sleeve; E=applying a splint on the affected arm. Each item was assessed on a 5-point Likert scale which values ranges from 0 (=no difficulty) to 4 (=cannot do the task). | Intention to treat (ITT) as defined as all randomized subjects; missing values were imputed by baseline value, i.e. zero change | Posted | Number | Participants | Baseline, Week 12 |
|
|
|
| Secondary | Change From Baseline to Final Visit in the Carer Burden Scale for Domain "Cleaning the Armpit of the Affected Arm" | The Carer Burden Scale evaluates the impact of antispastic medication on the physical burden of the carer. It consists of the following items: A=cleaning the palm of the affected hand; B=cutting the fingernails of the affected hand; C=Cleaning the armpit of the affected arm; D=putting the affected arm through the sleeve; E=applying a splint on the affected arm. Each item was assessed on a 5-point Likert scale which values ranges from 0 (=no difficulty) to 4 (=cannot do the task). | Intention to treat (ITT) as defined as all randomized subjects; missing values were imputed by baseline value, i.e. zero change | Posted | Number | Participants | Baseline, Final Visit of the Main Period (to be performed at week 12 after 1st injection at earliest, at week 20 at latest) |
|
|
|
| Secondary | Change From Baseline to Week 4 in the Carer Burden Scale for Domain "Putting the Affected Arm Through the Sleeve (e.g., Coat, Shirt, Jacket)" | The Carer Burden Scale evaluates the impact of antispastic medication on the physical burden of the carer. It consists of the following items: A=cleaning the palm of the affected hand; B=cutting the fingernails of the affected hand; C=Cleaning the armpit of the affected arm; D=putting the affected arm through the sleeve; E=applying a splint on the affected arm. Each item was assessed on a 5-point Likert scale which values ranges from 0 (=no difficulty) to 4 (=cannot do the task). | Intention to treat (ITT) as defined as all randomized subjects; missing values were imputed by baseline value, i.e. zero change | Posted | Number | Participants | Baseline, Week 4 |
|
|
|
| Secondary | Change From Baseline to Week 12 in the Carer Burden Scale for Domain "Putting the Affected Arm Through the Sleeve (e.g., Coat, Shirt, Jacket)" | The Carer Burden Scale evaluates the impact of antispastic medication on the physical burden of the carer. It consists of the following items: A=cleaning the palm of the affected hand; B=cutting the fingernails of the affected hand; C=Cleaning the armpit of the affected arm; D=putting the affected arm through the sleeve; E=applying a splint on the affected arm. Each item was assessed on a 5-point Likert scale which values ranges from 0 (=no difficulty) to 4 (=cannot do the task). | Intention to treat (ITT) as defined as all randomized subjects; missing values were imputed by baseline value, i.e. zero change | Posted | Number | Participants | Baseline, Week 12 |
|
|
|
| Secondary | Change From Baseline to Final Visit in the Carer Burden Scale for Domain "Putting the Affected Arm Through the Sleeve (e.g., Coat, Shirt, Jacket)" | The Carer Burden Scale evaluates the impact of antispastic medication on the physical burden of the carer. It consists of the following items: A=cleaning the palm of the affected hand; B=cutting the fingernails of the affected hand; C=Cleaning the armpit of the affected arm; D=putting the affected arm through the sleeve; E=applying a splint on the affected arm. Each item was assessed on a 5-point Likert scale which values ranges from 0 (=no difficulty) to 4 (=cannot do the task). | Intention to treat (ITT) as defined as all randomized subjects; missing values were imputed by baseline value, i.e. zero change | Posted | Number | Participants | Baseline, Final Visit of the Main Period (to be performed at week 12 after 1st injection at earliest, at week 20 at latest) |
|
|
|
| Secondary | Change From Baseline to Week 4 in the Carer Burden Scale for Domain "Applying a Splint on the Affected Arm" | The Carer Burden Scale evaluates the impact of antispastic medication on the physical burden of the carer. It consists of the following items: A=cleaning the palm of the affected hand; B=cutting the fingernails of the affected hand; C=Cleaning the armpit of the affected arm; D=putting the affected arm through the sleeve; E=applying a splint on the affected arm. Each item was assessed on a 5-point Likert scale which values ranges from 0 (=no difficulty) to 4 (=cannot do the task). | Intention to treat (ITT) as defined as all randomized subjects; missing values were imputed by baseline value, i.e. zero change | Posted | Number | Participants | Baseline, Week 4 |
|
|
|
| Secondary | Change From Baseline to Week 12 in the Carer Burden Scale for Domain "Applying a Splint on the Affected Arm" | The Carer Burden Scale evaluates the impact of antispastic medication on the physical burden of the carer. It consists of the following items: A=cleaning the palm of the affected hand; B=cutting the fingernails of the affected hand; C=Cleaning the armpit of the affected arm; D=putting the affected arm through the sleeve; E=applying a splint on the affected arm. Each item was assessed on a 5-point Likert scale which values ranges from 0 (=no difficulty) to 4 (=cannot do the task). | Intention to treat (ITT) as defined as all randomized subjects; missing values were imputed by baseline value, i.e. zero change | Posted | Number | Participants | Baseline, Week 12 |
|
|
|
| Secondary | Change From Baseline to Final Visit in the Carer Burden Scale for Domain "Applying a Splint on the Affected Arm" | The Carer Burden Scale evaluates the impact of antispastic medication on the physical burden of the carer. It consists of the following items: A=cleaning the palm of the affected hand; B=cutting the fingernails of the affected hand; C=Cleaning the armpit of the affected arm; D=putting the affected arm through the sleeve; E=applying a splint on the affected arm. Each item was assessed on a 5-point Likert scale which values ranges from 0 (=no difficulty) to 4 (=cannot do the task). | Intention to treat (ITT) as defined as all randomized subjects; missing values were imputed by baseline value, i.e. zero change | Posted | Number | Participants | Baseline, Final Visit of the Main Period (to be performed at week 12 after 1st injection at earliest, at week 20 at latest) |
|
|
|
| 4 |
| 73 |
| 10 |
| 73 |
| EG001 | Placebo | Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection Dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl; Mode of administration: intramuscular injection | 1 | 75 | 5 | 75 |
| Cellulitis | Infections and infestations | MedDRA (9.1) | Systematic Assessment |
|
| Epilepsy | Nervous system disorders | MedDRA (9.1) | Systematic Assessment |
|
| Hypertension | Vascular disorders | MedDRA (9.1) | Systematic Assessment |
|
| Intracranial haematoma | Nervous system disorders | MedDRA (9.1) | Systematic Assessment |
|
| Paraparesis | Nervous system disorders | MedDRA (9.1) | Systematic Assessment |
|
| Status epilepticus | Nervous system disorders | MedDRA (9.1) | Systematic Assessment |
|
| Vertigo | Ear and labyrinth disorders | MedDRA (9.1) | Systematic Assessment |
|
| Diarrhoea | Gastrointestinal disorders | MedDRA (9.1) | Systematic Assessment |
|
| Epilepsy | Nervous system disorders | MedDRA (9.1) | Systematic Assessment |
|
| Headache | Nervous system disorders | MedDRA (9.1) | Systematic Assessment |
|
| Hypercholesterolaemia | Metabolism and nutrition disorders | MedDRA (9.1) | Systematic Assessment |
|
| Hyperglycaemia | Metabolism and nutrition disorders | MedDRA (9.1) | Systematic Assessment |
|
| Vomiting | Gastrointestinal disorders | MedDRA (9.1) | Systematic Assessment |
|
No results to be published without written agreement by sponsor; manuscripts to be sent to sponsor at least 6 wks before submission. Sponsor to give written opinion within 30 d. Sponsor is entitled to exert influence on the contents of publications, to postpone publications up to 36 months after end of the study, and to name co-authors. In case of justified doubts of sponsor, the INVESTIGATOR will consider these doubts in the publication as long as the scientific neutrality is not affected.
| Week 12 |
|
| Final Visit |
|
| Week 8 |
|
| Week 12 |
|
| Final Visit |
|
| Week 8 |
|
| Week 12 |
|
| Final Visit |
|
| Week 8 |
|
| Week 12 |
|
| Final Visit |
|
| Week 8 |
|
| Week 12 |
|
| Final Visit |
|
| Change of "-1" points |
|
| Change of "0" points |
|
| Change of "+1" points |
|
| Change of "-1" points |
|
| Change of "0" points |
|
| Change of "+1" points |
|
| Change of "-1" points |
|
| Change of "0" points |
|
| Change of "+1" points |
|
| Missing |
|
| Change of "-1" points |
|
| Change of "0" points |
|
| Change of "+1" points |
|
| Missing |
|
| Change of "-1" points |
|
| Change of "0" points |
|
| Change of "+1" points |
|
| Missing |
|
| Change of "-1" points |
|
| Change of "0" points |
|
| Change of "+1" points |
|
| Change of "-1" points |
|
| Change of "0" points |
|
| Change of "+1" points |
|
| Missing |
|
| Change of "-1" points |
|
| Change of "0" points |
|
| Change of "+1" points |
|
| Missing |
|
| Change of "-1" points |
|
| Change of "0" points |
|
| Change of "+1" points |
|
| Missing |
|
| Change of "-1" points |
|
| Change of "0" points |
|
| Change of "+1" points |
|
| Missing |
|
| Change of "-1" points |
|
| Change of "0" points |
|
| Change of "+1" points |
|
| Change of "-1" points |
|
| Change of "0" points |
|
| Change of "+1" points |
|
| Missing |
|
| Change of "-1" points |
|
| Change of "0" points |
|
| Change of "+1" points |
|
| Missing |
|
| Change of "-1" points |
|
| Change of "0" points |
|
| Change of "+1" points |
|
| Missing |
|
| Change of "-1" points |
|
| Change of "0" points |
|
| Change of "+1" points |
|
| Missing |
|
| Change of "-1" points |
|
| Change of "0" points |
|
| Change of "+1" points |
|
| Change of "-1" points |
|
| Change of "0" points |
|
| Change of "+1" points |
|
| Missing |
|
| Change of "-1" points |
|
| Change of "0" points |
|
| Change of "+1" points |
|
| Missing |
|
| Change of "-1" points |
|
| Change of "0" points |
|
| Change of "+1" points |
|
| Missing |
|
| Change of "-1" points |
|
| Change of "0" points |
|
| Change of "+1" points |
|
| Missing |
|
| Change of "-1" points |
|
| Change of "0" points |
|
| Change of "+1" points |
|
| Change of "-1" points |
|
| Change of "0" points |
|
| Change of "+1" points |
|
| Missing |
|
| Change of "-1" points |
|
| Change of "0" points |
|
| Change of "+1" points |
|
| Change of "+2" points |
|
| Missing |
|
| Change of "-1" points |
|
| Change of "0" points |
|
| Change of "+1" points |
|
| Change of "+2" points |
|
| Missing |
|
| Change of "-1" points |
|
| Change of "0" points |
|
| Change of "+1" points |
|
| Change of "+2" points |
|
| Missing |
|
| Onset at Day 7, 8 or 9 |
|
| Onset at Day 10, 11 or 12 |
|
| Onset at Day 13, 14 or 15 |
|
| Onset at Day 16, 17 or 18 |
|
| Onset at Day 19, 20 or 21 |
|
| Onset at Day 22, 23 or 24 |
|
| Onset later than Day 25 |
|
| Censored |
|
| Moderate |
|
| Poor |
|
| Missing |
|
| Moderate |
|
| Poor |
|
| Missing |
|
| Moderate |
|
| Poor |
|
| No carer |
|
| Missing |
|
| Change of "-1" points |
|
| Change of "0" points |
|
| Change of "+1" points |
|
| Change of "+2" points |
|
| Change of "-1" points |
|
| Change of "0" points |
|
| Change of "+1" points |
|
| Change of "+2" points |
|
| Missing |
|
| Change of "-1" points |
|
| Change of "0" points |
|
| Change of "+1" points |
|
| Change of "+2" points |
|
| Missing |
|
| Change of "-1" points |
|
| Change of "0" points |
|
| Change of "+1" points |
|
| Change of "+2" points |
|
| Missing |
|
| Change of "-1" points |
|
| Change of "0" points |
|
| Change of "+1" points |
|
| Change of "+2" points |
|
| Missing |
|
| Change of "-1" points |
|
| Change of "0" points |
|
| Change of "+1" points |
|
| Change of "+2" points |
|
| Change of "-1" points |
|
| Change of "0" points |
|
| Change of "+1" points |
|
| Change of "+2" points |
|
| Missing |
|
| Change of "-1" points |
|
| Change of "0" points |
|
| Change of "+1" points |
|
| Change of "+2" points |
|
| Missing |
|
| Change of "-1" points |
|
| Change of "0" points |
|
| Change of "+1" points |
|
| Change of "+2" points |
|
| Missing |
|
| Change of "-1" points |
|
| Change of "0" points |
|
| Change of "+1" points |
|
| Change of "+2" points |
|
| Missing |
|
| Change of "-1" points |
|
| Change of "0" points |
|
| Change of "+1" points |
|
| Change of "+2" points |
|
| Change of "-1" points |
|
| Change of "0" points |
|
| Change of "+1" points |
|
| Change of "+2" points |
|
| Missing |
|
| Change of "-1" points |
|
| Change of "0" points |
|
| Change of "+1" points |
|
| Change of "+2" points |
|
| Missing |
|
| Change of "-1" points |
|
| Change of "0" points |
|
| Change of "+1" points |
|
| Change of "+2" points |
|
| Missing |
|
| Change of "-1" points |
|
| Change of "0" points |
|
| Change of "+1" points |
|
| Change of "+2" points |
|
| Missing |
|
| Change of "-1" points |
|
| Change of "0" points |
|
| Change of "+1" points |
|
| Change of "+2" points |
|
| Change of "-1" points |
|
| Change of "0" points |
|
| Change of "+1" points |
|
| Change of "+2" points |
|
| Missing |
|
| Change of "-1" points |
|
| Change of "0" points |
|
| Change of "+1" points |
|
| Change of "+2" points |
|
| Missing |
|
| Change of "-1" points |
|
| Change of "0" points |
|
| Change of "+1" points |
|
| Change of "+2" points |
|
| Missing |
|
| Change of "-1" points |
|
| Change of "0" points |
|
| Change of "+1" points |
|
| Change of "+2" points |
|
| Missing |
|
| Change of "-1" points |
|
| Change of "0" points |
|
| Change of "+1" points |
|
| Change of "+2" points |
|
| Change of "-1" points |
|
| Change of "0" points |
|
| Change of "+1" points |
|
| Change of "+2" points |
|
| Missing |
|
| Change of "-1" points |
|
| Change of "0" points |
|
| Change of "+1" points |
|
| Change of "+2" points |
|
| Missing |
|
| Change of "-1" points |
|
| Change of "0" points |
|
| Change of "+1" points |
|
| Change of "+2" points |
|
| Missing |
|
| Change of "-1" points |
|
| Change of "0" points |
|
| Change of "+1" points |
|
| Change of "+2" points |
|
| Missing |
|
| Less difficult |
|
| Unchanged |
|
| More difficult |
|
| Required for the first time |
|
| Missing |
|
| Less difficult |
|
| Unchanged |
|
| More difficult |
|
| Required for the first time |
|
| Missing |
|
| Less difficult |
|
| Unchanged |
|
| More difficult |
|
| Required for the first time |
|
| Missing |
|
| Less difficult |
|
| Unchanged |
|
| More difficult |
|
| Required for the first time |
|
| Missing |
|
| Less difficult |
|
| Unchanged |
|
| More difficult |
|
| Required for the first time |
|
| Missing |
|
| Less difficult |
|
| Unchanged |
|
| More difficult |
|
| Required for the first time |
|
| Missing |
|
| Less difficult |
|
| Unchanged |
|
| More difficult |
|
| Required for the first time |
|
| Missing |
|
| Less difficult |
|
| Unchanged |
|
| More difficult |
|
| Required for the first time |
|
| Missing |
|
| Less difficult |
|
| Unchanged |
|
| More difficult |
|
| Required for the first time |
|
| Missing |
|
| Less difficult |
|
| Unchanged |
|
| More difficult |
|
| Required for the first time |
|
| Missing |
|
| Less difficult |
|
| Unchanged |
|
| More difficult |
|
| Required for the first time |
|
| Missing |
|
| Less difficult |
|
| Unchanged |
|
| More difficult |
|
| Required for the first time |
|
| Missing |
|
| Less difficult |
|
| Unchanged |
|
| More difficult |
|
| Required for the first time |
|
| Missing |
|
| Less difficult |
|
| Unchanged |
|
| More difficult |
|
| Required for the first time |
|
| Missing |
|
| Less difficult |
|
| Unchanged |
|
| More difficult |
|
| Required for the first time |
|
| Missing |
|